SCHEMBL19686974

SCHEMBL19686974

Cc1cnc(-c2nc(NC3CCC(F)(F)CC3)cc(N3CCOCC3)n2)s1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.43
KCNH2 Q12809 1/20 0.43
IDH1 O75874 4/20 0.40
IRAK4 Q9NWZ3 1/20 0.39
CCNT1 O60563 1/20 0.38
RAF1 P04049 2/20 0.37
BRAF P15056 1/20 0.37
PIK3CA P42336 3/20 0.37
PDE10A Q9Y233 2/20 0.36
AKT1 P31749 1/20 0.35
MTOR P42345 1/20 0.35
PIK3R2 O00459 1/20 0.35
CHRM3 P20309 2/20 0.34
PDE4A P27815 2/20 0.34
PDE4B Q07343 2/20 0.34
PDE4C Q08493 2/20 0.34
PDE4D Q08499 2/20 0.34
NUDT1 P36639 1/20 0.34
HRH4 Q9H3N8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21166130 0.91 JAK2 (0.40) JAK2KCNH2IRAK4CCNT1RAF1
SCHEMBL19686649 0.84 IDH1 (0.44) IDH1IRAK4PDE10APIK3R2
SCHEMBL19686678 0.84 IDH1 (0.37) IDH1CCNT1RAF1PIK3CAPDE10A
SCHEMBL19686393 0.83 ADORA2A (0.40) IDH1IRAK4CCNT1PIK3CAPIK3R2
SCHEMBL19686473 0.81 IDH1 (0.41) IDH1IRAK4PDE10APIK3R2CHRM3
SCHEMBL19686843 0.80 IDH1 (0.59) IDH1RAF1BRAF
SCHEMBL19686975 0.80 IDH1 (0.45) IDH1IRAK4CCNT1RAF1PIK3CA
SCHEMBL19686596 0.79 IDH1 (0.60) JAK2KCNH2IDH1CCNT1PIK3CA
SCHEMBL19686956 0.79 IDH1 (0.43) IDH1CCNT1PIK3CAPDE10ACHRM3
SCHEMBL19686916 0.79 IDH1 (0.50) JAK2KCNH2IDH1CCNT1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 JAK2 2732/4885KCNH2 22/4885IDH1 3017/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 JAK2 2732/4885KCNH2 22/4885IDH1 3017/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 JAK2 2732/4885KCNH2 22/4885IDH1 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.